← Leaderboards
James G. Moe
Oligomerix, Inc
$22,112,369
Attributed
$22,112,369
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.6M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,112,369 · 9
By mechanism
R44$21,253,368 · 6
R43$859,001 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposProgramsTau ProteinsS DiseasePharmaceutical PreparationsTau AggregationMouse ModelDosePreventSmall MoleculeIn VivoLeadCostPathologyTauopathiesCaregiversAmericanSeriesIn VitroCause Of DeathChronicBaseUnited StatesSafety Study
Grant awards (26)
A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery Period$499,879
R44 · FY2025 · AG · contact PI
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD$1,497,873
R44 · FY2024 · AG · contact PI
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD$1,496,276
R44 · FY2023 · AG · contact PI
A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study$1,367,955
R44 · FY2023 · AG · contact PI
A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study$1,124,972
R44 · FY2022 · AG · contact PI
Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD$456,646
R44 · FY2022 · AG · contact PI
Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD$160,363
R44 · FY2022 · AG · contact PI
Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD$1,290,570
R44 · FY2021 · AG · contact PI
Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD$1,452,237
R44 · FY2020 · AG · contact PI
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD$999,937
R44 · FY2020 · AG · contact PI
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD$954,537
R44 · FY2020 · AG · contact PI
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development for ADRD$1,228,934
R44 · FY2019 · AG · contact PI
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD$999,982
R44 · FY2019 · AG · contact PI
Tau oligomer platform validation using lead series candidate in htau mice$983,729
R44 · FY2019 · AG · contact PI
Tau oligomer platform validation using lead series candidate in htau mice$373,923
R44 · FY2019 · AG · contact PI
Tau oligomer platform validation using lead series candidate in htau mice$999,248
R44 · FY2018 · AG · contact PI
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD$499,433
R44 · FY2018 · AG · contact PI
Tau Oligomer Platform Validation Using Lead Series Candidate in htau Mice$749,795
R44 · FY2017 · AG · contact PI
Development of an Alzheimer's disease specific antibody biomarker for a tau oligomer fragment$302,112
R43 · FY2017 · AG · contact PI
Tau Oligomer Platform Validation Using Lead Series Candidate in htau Mice$749,795
R44 · FY2016 · AG · contact PI
High throughput tau oligomer drug screening assay for Alzheimer's disease$814,009
R44 · FY2014 · AG · contact PI
High throughput tau oligomer drug screening assay for Alzheimer's disease$903,675
R44 · FY2013 · AG · contact PI
High throughput tau oligomer assay for drug screening for Alzheimer's disease$732,203
R44 · FY2011 · AG · contact PI
High throughput tau oligomer assay for drug screening for Alzheimer's disease$917,397
R44 · FY2010 · AG · contact PI
DEVELOPMENT OF NOVEL BIOMARKERS FOR ALZHEIMER'S DISEASE$323,291
R43 · FY2009 · AG · contact PI
High throughput tau oligomer assay for drug screening for Alzheimer's disease$233,598
R43 · FY2007 · AG · contact PI